DexCom Stock Is the Worst Performer in the S&P 500. Here’s Why.
1. DexCom raises 2025 revenue guidance to $4.63-$4.65 billion, indicating 15% growth. 2. Interim CEO warns 2026 revenue might fall short of analyst forecasts. 3. Third-quarter revenue surged 22% to $1.209 billion, exceeding expectations. 4. Shares plummeted over 17% after cautious growth outlook was presented. 5. Analysts see potential buying opportunities despite recent stock declines.